GlassScriptPhysician profile
Jyothi Dodlapati
NPI 1467402602
$1,722.25
in general payments reported to CMS, 2019-2025
31 companies · $713 in 2025
The $713 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $117 · 2021: $116 · 2022: $127 · 2023: $353 · 2024: $296 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $197.60 | 2020-2025 | Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $188.35 | 2022-2023 | Opdivo |
| Adc Therapeutics America, INC. | $122.79 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.08 | 2021 | |
| Eisai INC. | $107.50 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $96.45 | 2023-2024 | |
| Medtronic, INC. | $96.16 | 2024 | Endo Gia Ultra |
| Exelixis INC. | $92.52 | 2023 | Cabometyx |
| Agios Pharmaceuticals, INC. | $85.19 | 2023 | Pyrukynd |
| Taiho Oncology, INC. | $58.82 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.52 | 2025 | |
| Janssen Biotech, INC. | $43.97 | 2025 | Darzalex, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $43.65 | 2022-2025 | Keytruda |
| Aveo Pharmaceuticals, INC. | $37.40 | 2025 | |
| Beigene USA, INC. | $35.80 | 2024 | Brukinsa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $30.34 | 2024 | Reblozyl |
| Glaxosmithkline, LLC. | $30.16 | 2025 | Blenrep, Jemperli |
| Daiichi Sankyo INC. | $26.50 | 2023 | Injectafer |
| Geron Corporation | $26.41 | 2025 | Rytelo |
| Caris Mpi, INC. | $25.56 | 2025 | Mi Cancer Seek |
| Janssen Scientific Affairs, LLC | $24.97 | 2025 | Talvey, Tecvayli, Darzalex |
| Amgen INC. | $22.43 | 2024 | Nplate, Vectibix, Xgeva |
| Gilead Sciences, INC. | $21.45 | 2025 | Trodelvy |
| Array Biopharma INC | $20.79 | 2025 | Braftovi |
| Pfizer INC. | $19.39 | 2025 | |
| Incyte Corporation | $18.98 | 2025 | Niktimvo, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $17.97 | 2023 | Ninlaro |
| Lilly USA, LLC | $17.90 | 2023 | Verzenio |
| Regeneron Healthcare Solutions, INC. | $17.41 | 2025 | Libtayo |
| Astellas Pharma US INC | $17.22 | 2025 | Padcev |
| Stemline Therapeutics INC. | $15.97 | 2025 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyothi Dodlapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.